Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/13993003.00440-2018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic Thromboembolic Pulmonary Hypertension as -Associated Vascular Disease.
JACC Asia
December 2024
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Reply to Letter to the Editor Regarding: "Unilateral Chronic Thromboembolic Pulmonary Disease: Do Patients Benefit From Thromboendarterectomy?".
Heart Lung Circ
January 2025
Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:
Letter to the Editor Regarding: "Unilateral Chronic Thromboembolic Pulmonary Disease: Do Patients Benefit From Thromboendarterectomy? Case Series From Three CTEPH Centres" By Rashidi et al. Heart Lung Circ. 2024;33(11):1574-81.
Heart Lung Circ
January 2025
University Centre for Research & Development Department of Pharmaceutical Sciences, Chandigarh University, Mohali, Punjab, India.
Treatment of very high risk membranous nephropathy complicated by pulmonary embolism with glucocorticoids and rituximab: Case report.
Medicine (Baltimore)
January 2025
Division of Nephrology, Department of Medicine, National University Hospital, Singapore.
Rationale: We report the efficacy of combination prednisolone and intravenous (IV) rituximab as an immunosuppressive regimen for a young male presenting with extensive venous thromboembolism including a submassive pulmonary embolism secondary to life-threatening nephrotic syndrome from very high risk anti-phospholipase-A2 receptor (PLA2R) positive membranous nephropathy. Initial treatment was with mechanical thrombectomy and anticoagulation. Thereafter, oral prednisolone was initiated to induce remission, during a period of uninterrupted anticoagulation.
View Article and Find Full Text PDFThe main treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) is radical surgery, pulmonary thromboendarterectomy (PEA). However, about 40% of patients with CTEPH are inoperable due to distal pulmonary vascular lesions or the severity of hemodynamic disorders. Almost 30% of patients with CTEPH experience persistent or recurrent pulmonary hypertension after surgery, that requires a drug treatment with PAH-specific drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!